Market Cap 134.30M
Revenue (ttm) 53.40M
Net Income (ttm) 2.93M
EPS (ttm) N/A
PE Ratio 23.86
Forward PE 66.80
Profit Margin 5.49%
Debt to Equity Ratio 0.00
Volume 581,000
Avg Vol 803,902
Day's Range N/A - N/A
Shares Out 80.42M
Stochastic %K 48%
Beta -0.25
Analysts Strong Sell
Price Target $11.00

Company Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 696 9345
Address:
2 University Plaza, Suite 100, Hackensack, United States
AverageTraders
AverageTraders Dec. 4 at 11:38 PM
What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. added $ADGM $PLX $IBRX $AQST to
1 · Reply
CliffordCapital
CliffordCapital Dec. 4 at 4:02 PM
$PLX P2 anybody??
1 · Reply
Artfldgr
Artfldgr Dec. 3 at 9:12 PM
$PLX i fed both of these comments in to ChatGPT and asked it to review it in terms of other retail investors i found that out of all the variables that you can know about a company or stock, that timing is the one thing that is the most flakey.
0 · Reply
Artfldgr
Artfldgr Dec. 3 at 9:07 PM
$PLX People talk about “just be patient,” but patience only works when you understand what you own and why an outcome is eventual. This isn’t about picking a random stock and waiting. In many fields—medical, biotech, new products—you can often see what will happen, but you can’t know when. Real-world adoption doesn’t follow your timetable, and neither does investor recognition. You may be certain the value will be realized, but it could be one year, three years, or longer. That uncertainty in timing is normal, not a failure. When you know the fundamentals guarantee an eventual shift, the waiting becomes strategic, not hopeful. That distinction is one of the most important parts of successful investing.
1 · Reply
Artfldgr
Artfldgr Dec. 3 at 9:03 PM
$PLX Most investors judge a stock only by steady, visible progress. But real gains often come in bursts, not smooth lines. That’s why I use a simple benchmark: the 7:10 / 10:7 rule. • 7 years at 10% doubles your money. • 10 years at 7% doubles your money. Now here’s the key: a stock that grows 0% for 9.9 years and then doubles in the final month delivers the same long-term return as one that climbs steadily. If you only look for constant upward movement, you’ll think you’re “failing” and you may sell right before the payoff. Many great investments sit still, fake breakouts, look dead—until they suddenly move. The patience to hold through stagnation, combined with knowing the long-term doubling math, is a major reason I’ve been able to hit 30–40% annualized returns. the major plus for those that don't move is you have time to accumulate and don't have to put all of it down at once.
0 · Reply
pennyman
pennyman Dec. 3 at 8:59 PM
$PLX I added more 5-15-26 $2.50 calls today at .15. Time will tell. GLTA
1 · Reply
PLX_BULLS
PLX_BULLS Dec. 3 at 6:19 PM
$PLX Almost 22% tute holding as of recent. Nice buy in here!
0 · Reply
swarty
swarty Dec. 3 at 5:41 PM
$PLX This feels like another $0.99 moment where you can cost average down again (if you want). It won't stay here long. There is no logical reason this isn't going to climb again. As disappointing as the price is right now, I still cannot find a negative side to this stock. It's got nothing but runway as it stands right now.
2 · Reply
Artfldgr
Artfldgr Dec. 3 at 5:28 PM
$PLX “You told me to look into Minnesota and their fraud on visas and their programs: 50% of them are fraudulent, which means that that wacko Gov. (Tim) Walz either is an idiot or he did it on purpose — and I think he’s both, sir,” Noem said
0 · Reply
ed29
ed29 Dec. 3 at 11:03 AM
1 · Reply
Latest News on PLX
Why Is Protalix BioTherapeutics Stock Falling On Friday?

Oct 17, 2025, 11:23 AM EDT - 6 weeks ago

Why Is Protalix BioTherapeutics Stock Falling On Friday?


Protalix BioTherapeutics to Present at Investor Summit Virtual

Sep 11, 2025, 10:55 AM EDT - 3 months ago

Protalix BioTherapeutics to Present at Investor Summit Virtual


Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Dec 23, 2024, 6:50 AM EST - 1 year ago

Protalix BioTherapeutics Issues 2025 Letter to Stockholders


AverageTraders
AverageTraders Dec. 4 at 11:38 PM
What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. added $ADGM $PLX $IBRX $AQST to
1 · Reply
CliffordCapital
CliffordCapital Dec. 4 at 4:02 PM
$PLX P2 anybody??
1 · Reply
Artfldgr
Artfldgr Dec. 3 at 9:12 PM
$PLX i fed both of these comments in to ChatGPT and asked it to review it in terms of other retail investors i found that out of all the variables that you can know about a company or stock, that timing is the one thing that is the most flakey.
0 · Reply
Artfldgr
Artfldgr Dec. 3 at 9:07 PM
$PLX People talk about “just be patient,” but patience only works when you understand what you own and why an outcome is eventual. This isn’t about picking a random stock and waiting. In many fields—medical, biotech, new products—you can often see what will happen, but you can’t know when. Real-world adoption doesn’t follow your timetable, and neither does investor recognition. You may be certain the value will be realized, but it could be one year, three years, or longer. That uncertainty in timing is normal, not a failure. When you know the fundamentals guarantee an eventual shift, the waiting becomes strategic, not hopeful. That distinction is one of the most important parts of successful investing.
1 · Reply
Artfldgr
Artfldgr Dec. 3 at 9:03 PM
$PLX Most investors judge a stock only by steady, visible progress. But real gains often come in bursts, not smooth lines. That’s why I use a simple benchmark: the 7:10 / 10:7 rule. • 7 years at 10% doubles your money. • 10 years at 7% doubles your money. Now here’s the key: a stock that grows 0% for 9.9 years and then doubles in the final month delivers the same long-term return as one that climbs steadily. If you only look for constant upward movement, you’ll think you’re “failing” and you may sell right before the payoff. Many great investments sit still, fake breakouts, look dead—until they suddenly move. The patience to hold through stagnation, combined with knowing the long-term doubling math, is a major reason I’ve been able to hit 30–40% annualized returns. the major plus for those that don't move is you have time to accumulate and don't have to put all of it down at once.
0 · Reply
pennyman
pennyman Dec. 3 at 8:59 PM
$PLX I added more 5-15-26 $2.50 calls today at .15. Time will tell. GLTA
1 · Reply
PLX_BULLS
PLX_BULLS Dec. 3 at 6:19 PM
$PLX Almost 22% tute holding as of recent. Nice buy in here!
0 · Reply
swarty
swarty Dec. 3 at 5:41 PM
$PLX This feels like another $0.99 moment where you can cost average down again (if you want). It won't stay here long. There is no logical reason this isn't going to climb again. As disappointing as the price is right now, I still cannot find a negative side to this stock. It's got nothing but runway as it stands right now.
2 · Reply
Artfldgr
Artfldgr Dec. 3 at 5:28 PM
$PLX “You told me to look into Minnesota and their fraud on visas and their programs: 50% of them are fraudulent, which means that that wacko Gov. (Tim) Walz either is an idiot or he did it on purpose — and I think he’s both, sir,” Noem said
0 · Reply
ed29
ed29 Dec. 3 at 11:03 AM
1 · Reply
ed29
ed29 Dec. 3 at 11:03 AM
$PLX Let's remember to choose wisely. Today I choose to be and feel all these things!
0 · Reply
ed29
ed29 Dec. 3 at 10:58 AM
$PLX https://x.com/pascal_bornet/status/1995402771328102712 Pretty amazing stuff above.
2 · Reply
BryGuy29
BryGuy29 Dec. 3 at 4:23 AM
$PLX knowing this company, I wouldn’t even be surprised if they did not PR the first gout dosing in Dec, as they’ve said they would. Management is no good here.
2 · Reply
dannymac65
dannymac65 Dec. 2 at 10:21 PM
$PLX And now for some winter levity.
0 · Reply
Social_Idiot
Social_Idiot Dec. 2 at 9:36 PM
$PLX This morning, I thought Dror finally hit par value (0.001 common, 0.0001 preferred)
0 · Reply
Social_Idiot
Social_Idiot Dec. 2 at 5:28 PM
$PLX It's come to my attention that there is a new patent for PLX published Oct 30 2025, filed May 8, 2025 Looks like an update to the Feb 2024 filing. They added phase 1 data. METHODS OF TREATING DISEASES ASSOCIATED WITH ELEVATED URIC ACID https://worldwide.espacenet.com/patent/search/family/097447289/publication/US2025332228A1?q=US2025332228A1
0 · Reply
Social_Idiot
Social_Idiot Dec. 2 at 5:14 PM
0 · Reply
PickStocker
PickStocker Dec. 2 at 4:50 PM
$PLX Just looking at the stock price… looks like dead money (once again). Gotta lean on those patient testimonials to resist selling this turd. 💩Maybe next year’s ERs will finally deliver that long-awaited pleasant surprise.
0 · Reply
ToRni27
ToRni27 Dec. 2 at 4:23 PM
$PLX The rats are leaving the sinking ship.
0 · Reply
CliffordCapital
CliffordCapital Dec. 2 at 4:14 PM
$PLX nice! Back to 1.50‘s! 😂 Then we can go up to 2.50$‘s again with good Q4 and drop back to 1.50‘s on slow Q1/ Q2/ sales in 26. 🥹Sorry but this is just dead money until 2027.. 😢
3 · Reply
ToRni27
ToRni27 Dec. 2 at 4:12 PM
$PLX bleeding everday… thanks to management „at least 12 months“ lol like 29M cash on hand is nothing. No insider buys so its not cheap yet.
0 · Reply
milt0n
milt0n Dec. 2 at 2:04 PM
$PLX Greece it seems comes to a different conclusion than Australia and some of these other countries that have denied reimbursement on the basis of cost. https://www.ispor.org/docs/default-source/cti-meeting-21305-documents/5d898b2a-9a41-40a1-820e-5d7b8c0bee83.pdf?sfvrsn=50cd8752_0 "Treatment with pegunigalsidase-alfa results in less costs and higher QALYs as health outcomes, compared to currently used ERTs for adult patients with FD in Greece."
1 · Reply